OliX Pharmaceuticals, Inc.
KOSDAQ-listed RNAi biotech developing and out-licensing therapeutics based on its proprietary self-delivering asymmetric siRNA (cp-asiRNA) platform.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KOSDAQ in 2018, OliX Pharmaceuticals is a drug developer specializing in RNA interference (RNAi) platform technology. It has secured proprietary self-delivering asymmetric siRNA (cp-asiRNA) technology to develop therapeutics for intractable diseases, improving intracellular delivery efficiency by conjugating hydrophobic moieties for extrahepatic delivery and using GalNAc with its own proprietary linker for liver delivery, and is also developing the next-generation GalNAc-bi-asiRNA platform capable of targeting two genes simultaneously. Its technology can target any gene through sequence changes alone and shortens candidate selection to under one year, and the company monetizes its RNAi platform and pipeline-related technologies by licensing them to domestic and international pharmaceutical companies.
R&D and key agreements
Source: DART corporate disclosurecp-asiRNA(자가전달 비대칭 siRNA) · 플랫폼 기술 · Proprietary self-delivering asymmetric siRNA platform; candidate selection shortened to under one year
GalNAc-bi-asiRNA · 연구개발중 · Next-generation platform capable of targeting two genes simultaneously
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition